B. A. Teicher, S. A. Holden, G. Ara, T. Korbut, and K. Manon, “Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in Lewis lung carcinoma,” Cancer Chemothe Pharmacol, Vol. 38, pp. 169– 177, 1996.

has been cited by the following article:

• TITLE: Synthesis, Characterization and Anti-Angiogenic Effects of Novel 5-Amino Pyrazole Derivatives on Ehrlich Ascites Tumor [EAT] Cells in-Vivo

  AUTHORS: H. Raju, S. Chandrappa, M. K. Ramakrishna, T. S. Nagamani, H. Ananda, S. M. Byregowda, K. S. Rangappa

  KEYWORDS: 1H-Pyrazol, Aryl Isothiocyanates, Ehrlich Ascites Tumor [EAT] Cells, Anti-Angiogenesis

  JOURNAL NAME: Journal of Cancer Therapy, Vol.1 No.1, March 24, 2010

  ABSTRACT: In search of synthetic chemotherapeutic substances capable of inhibiting, retarding, or reversing the process of multi-stage carcinogenesis, we synthesized a series of novel 5-amino pyrazole derivatives 11(a-h) by a nucleophilic substitution reaction and characterized by 1H nuclear magnetic resonance (NMR), liquid chromatography mass spectrometry (LC/MS), Fourier-transform infrared (FTIR), and elemental analysis. These novel compounds were evaluated for their efficacy in inhibiting Ehrlich ascites tumor [EAT] cells in-vivo. In the present study we designed, synthesized, characterized and investigate the anti-angiogenic effects of these compounds, on Ehrlich ascites tumor [EAT] cells in-vivo. The compounds were subsequently tested for their ability to inhibit neovascularisation in chorio allantoin membrane (CAM) model. From the Structure Activity Relationship (SAR) studies, it reveals that, the substitution at N-terminal in pyrazole ring plays key role in the antitumor and anti-angiogenic effects.